Cargando…
Incidence of Differentiation Syndrome Associated with Treatment Regimens in Acute Myeloid Leukemia: A Systematic Review of the Literature
Differentiation syndrome (DS) is a potentially fatal adverse drug reaction caused by the so-called differentiating agents such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), used for remission induction in the treatment of the M3 subtype of acute myeloid leukemia (AML), acute promyelo...
Autores principales: | Gasparovic, Lucia, Weiler, Stefan, Higi, Lukas, Burden, Andrea M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603213/ https://www.ncbi.nlm.nih.gov/pubmed/33081000 http://dx.doi.org/10.3390/jcm9103342 |
Ejemplares similares
-
Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
por: Shapiro, Roman M., et al.
Publicado: (2018) -
Venetoclax-containing regimens in acute myeloid leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2021) -
The “7+3” regimen in acute myeloid leukemia
por: Rowe, Jacob M.
Publicado: (2022) -
A novel mesenchymal stem cell-based regimen for acute myeloid leukemia differentiation therapy
por: Sun, Luchen, et al.
Publicado: (2023) -
Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen
por: Ali, Alaa M., et al.
Publicado: (2017)